Ex-Vivo percutaneous absorption of enrofloxacin: Comparison of LMOG organogel vs. pentravan cream

Abstract

The objective of this study was to investigate the percutaneous absorption of enrofloxacin from two base formulations, Pentravan® cream and LMOG organogel. Ex-vivo experiments were carried out on pig ear skin. The percutaneous permeation through pig skin of two formulations containing 5wt% of enrofloxacin was measured and compared using Franz diffusion cells. At appropriate intervals up to 120h, diffusion samples were taken and analyzed using HPLC assays. Permeation profiles were established and the parameters Tlag and flux values were calculated. In this ex-vivo study, the flux values were 0.35μgcm−2h−1 for Pentravan® and 1.22μgcm−2h−1 for LMOG organogel, corresponding respectively to 7.9 % and 29.3 % of enrofloxacin absorbed after 120h by these formulations. The lag time (Tlag) of Pentravan® and organogel were 6.32 and 0.015h respectively. The absorption time to reach the antibiotic concentration of enrofloxacin (2μgmL−1) in the receptor was 60h with Pentravan® and 30h with the organogel, suggesting more effective treatment by the latter. Enrofloxacin contained in organogel could be absorbed through pig ear skin 3.7 times greater than that in Pentravan® (commercial formulation). This study demonstrates the perspective of organogel formulations as potential drug delivery systems.